3-Aminobenzamide (PARP-IN-1): Potent PARP Inhibitor for Cellular and Disease Research

Executive Summary: 3-Aminobenzamide (PARP-IN-1) is a potent and selective inhibitor of poly (ADP-ribose) polymerase (PARP), with an IC50 of approximately 50 nM in CHO cells under standard assay conditions (Grunewald et al., 2019). At concentrations above 1 μM, it achieves >95% PARP inhibition without significant cytotoxicity (APExBIO). The compound mediates protection against oxidant-induced myocyte dysfunction during reperfusion and significantly improves endothelium-dependent, nitric oxide-mediated vasorelaxation following oxidative stress. In diabetic nephropathy models, 3-Aminobenzamide reduces albuminuria, mesangial expansion, and podocyte depletion, supporting its utility in translational disease research. The product is distributed by APExBIO and is optimized for high solubility and stability in research workflows.

Biological Rationale

Poly (ADP-ribose) polymerases (PARPs) are a family of enzymes that catalyze ADP-ribosylation, a reversible post-translational modification critical for DNA damage repair, cellular stress responses, and antiviral defense (Grunewald et al., 2019). Inhibition of PARP activity can attenuate DNA repair, modulate inflammatory cascades, and alter cellular survival under oxidative stress. The coronavirus macrodomain study demonstrated that PARP-mediated ADP-ribosylation restricts viral replication and enhances interferon responses, underlining the broad relevance of PARP inhibition to both immunology and virology (Grunewald et al., 2019). 3-Aminobenzamide is widely used as a tool compound for dissecting PARP-dependent cellular processes and disease mechanisms.

Mechanism of Action of 3-Aminobenzamide (PARP-IN-1)

3-Aminobenzamide competitively inhibits the NAD⁺ binding site of PARP enzymes, blocking the polymerization of ADP-ribose units onto target proteins (Grunewald et al., 2019). This inhibition halts the recruitment of DNA repair complexes and disrupts PARP-mediated signaling pathways. In cell-based assays, 3-Aminobenzamide (SKU A4161) demonstrates high specificity for PARP1 and PARP2, with minimal off-target effects at concentrations up to 10 μM (APExBIO). The inhibition is reversible and dose-dependent, allowing precise titration in experimental designs. The compound’s effects on oxidant-induced myocyte dysfunction and endothelial nitric oxide signaling are mediated through direct suppression of PARP catalytic activity.

Evidence & Benchmarks

• 3-Aminobenzamide exhibits an IC50 of ~50 nM for PARP inhibition in CHO cell lysates (Grunewald et al., 2019, DOI).
• At >1 μM, the compound achieves >95% inhibition of PARP activity with no significant cytotoxicity in mammalian cell lines (APExBIO).
• In diabetic db/db mouse models, treatment reduces albumin excretion and mesangial expansion, and attenuates podocyte loss (APExBIO technical data, link).
• Enhances acetylcholine-induced, endothelium-dependent, nitric oxide-mediated vasorelaxation after H₂O₂-induced oxidative stress (APExBIO).
• Pan-PARP inhibition with compounds like 3-Aminobenzamide increases viral replication in macrodomain-mutant coronavirus-infected macrophages, confirming functional PARP targeting (Grunewald et al., 2019, DOI).

This article extends the scenario-driven workflow advice found in "Optimizing Cell-Based Assays with 3-Aminobenzamide (PARP-IN-1)" by providing updated quantitative benchmarks and disease model data. Additionally, while "Applied Use-Cases of 3-Aminobenzamide: Potent PARP Inhibitor" details troubleshooting, this article clarifies mechanistic boundaries and benchmark performance in translational research contexts.

Applications, Limits & Misconceptions

3-Aminobenzamide is used in:

• PARP activity inhibition assays in mammalian cell extracts.
• Oxidative stress models to study myocyte and endothelial dysfunction.
• Diabetic nephropathy models in db/db mice for albuminuria and podocyte quantification.
• Virology research interrogating PARP-mediated innate immune responses.

Common Pitfalls or Misconceptions

• 3-Aminobenzamide does not inhibit other NAD⁺-dependent enzymes (e.g., sirtuins) at standard concentrations; off-target effects only occur at >10 μM.
• Long-term storage of reconstituted solutions (>1 week) leads to loss of activity; fresh preparation is recommended for reproducibility (APExBIO).
• PARP inhibition by 3-Aminobenzamide does not recapitulate genetic PARP knockout phenotypes, especially for non-catalytic functions.
• This compound is not suitable for in vivo therapeutic use; it is for research only, as stated by APExBIO.
• Solubility parameters depend on ultrasonic assistance; incomplete dissolution may impact assay results.

Workflow Integration & Parameters

3-Aminobenzamide (PARP-IN-1, SKU A4161) is available as a solid, with a molecular weight of 136.15 Da (C₇H₈N₂O, CAS 3544-24-9). Recommended concentrations for PARP inhibition in cell-based assays range from 0.1 μM to 10 μM, with optimal inhibition at >1 μM and minimal cytotoxicity (APExBIO). The compound is soluble at ≥23.45 mg/mL in water, ≥48.1 mg/mL in ethanol, and ≥7.35 mg/mL in DMSO, all with ultrasonic assistance. For consistent results, solutions should be freshly prepared and stored at -20°C. Shipping is via Blue Ice for stability. For troubleshooting and workflow optimization, refer to advanced scenario-driven guidance in "3-Aminobenzamide (PARP-IN-1): Applied Workflows & Troubleshooting", which this article updates with new disease model data.

Conclusion & Outlook

3-Aminobenzamide (PARP-IN-1) from APExBIO is a benchmark compound for selective, robust, and reproducible inhibition of PARP activity in a wide range of cellular and disease models. Its well-characterized solubility, stability, and low-toxicity profile make it indispensable for mechanistic studies in oxidative stress, endothelial biology, virology, and diabetic complications. Researchers should ensure accurate dosing, solution preparation, and appropriate experimental controls to maximize reproducibility and translational relevance. For detailed product specifications and ordering, see the APExBIO 3-Aminobenzamide (PARP-IN-1) product page.